Apnimed, Inc. is progressing its AD109 drug (Oxnimbi) for obstructive sleep apnea, showing strong Phase 3 results and a clear advantage over CPAP therapy. The company has a fully funded plan for commercialization, with an NDA under FDA review and a PDUFA date set for February 2027. Financially, Apnimed is shifting from research to pre-commercial activities, supported by a solid cash position ensuring several years of operational runway. The investment outlook depends on FDA approval, market adoption, and managing payer and real-world usage risks.
Gold prices fell more than 1% after US data showed initial jobless claims steady at 206,000, indicating a stable labor market. This stability suggests the Federal Reserve may feel confident to raise interest rates in its upcoming policy meeting. The ...
The Breakwave Tanker Shipping ETF (BWET) surged an extraordinary 3,000% in 2026, rising from $18.73 to $583.39 by September 10. This dramatic increase is linked to escalating hostilities between the U.S., Israel, and Iran, which have driven tanker ra...
Ethereum is trading around $2,470 following a strong 37% rally in late August, forming a bullish flag pattern that suggests a potential rise to $3,050 if it breaks current consolidation. The $3,050 target aligns with a historical resistance zone, mak...
Deutsche Bank acknowledged positive data from AstraZeneca's tozorakimab for chronic obstructive pulmonary disease (COPD), presented at the ERS conference, supporting the drug's commercial potential. Despite this, the bank maintained a 'sell' rating o...
Canada has advanced XRP adoption by allowing options on Canadian XRP ETFs to be traded in the US, following regulatory approval by the Canadian Derivatives Clearing Corporation. This move provides US investors access to XRP volatility through regulat...
